Company Research Report: Northwest Biotherapeutics, Inc.

Company Overview

• Name: Northwest Biotherapeutics, Inc.

• Mission: Northwest Biotherapeutics is focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.

• Founding Date: No information is available.

• Founders: No information is available.

• Key People:

• Linda F. Powers - Chief Executive Officer

• Les Goldman - Senior Vice President, General Counsel

• Marnix L. Bosch - Ph.D. Chief Technical Officer

• Alton L. Boynton - Chief Scientific Officer

• Headquarters: 4800 Montgomery Lane, Suite 800, Bethesda, MD 20814

• Number of Employees: No information is available.

• Revenue: No information is available.

• Company's Renown: Known for developing DCVax® personalized immune therapies for solid tumor cancers using dendritic cell-based technology.

Products

• DCVax® – L

• Description: DCVax-L is a personalized vaccine made with cancer antigens from tumor lysate, incorporating the full set of tumor antigens.

• Key Features:

• Designed for solid tumor cancers where tumors can be surgically removed.

• Target the full set of biomarkers on a patient’s tumor.

• Non-toxic with no serious adverse events reported.

• DCVax® – Direct

• Description: Designed for inoperable tumors and incorporates tumor antigens in situ within the patient's body.

• Key Features:

• Suitable for non-resectable solid tumors.

• Partially matured dendritic cells are injected directly into tumors.

• Mobilizes the immune response within the patient's body.

• DCVax® – Prostate

• Description: Specifically designed for late-stage, hormone-independent prostate cancer.

• Key Features:

• Uses a proprietary antigen, PSMA.

• Targets diffuse cancer cells found in late-stage prostate cancer.

Recent Developments

• July 3, 2024: Announced positive votes at the Annual Shareholders Meeting indicating strong progress and growth opportunities.

• June 17, 2024: Entered an exclusive in-license agreement with Roswell Park Comprehensive Cancer Center to acquire a portfolio of Dendritic Cell Technology and Intellectual Property.

• March 21, 2024: Appointment of Mr. Pat Sarma to the Board of Directors, replacing Mr. Jerry Jasinowski.

• February 6, 2024: Completion of development work for the Flaskworks manufacturing system and engagement of a vendor to produce GMP-grade units.

• December 21, 2023: Submitted a Marketing Authorization Application to the UK MHRA for DCVax®-L for glioblastoma.

Clinical Trials

• DCVax® – L: Currently in Phase III trials for newly diagnosed glioblastoma multiforme (GBM).

• DCVax® – Direct: Undergoing Phase I/II trials for direct injection into all types of inoperable solid tumor cancers.

• DCVax® – Prostate: Cleared for a Phase III trial for late-stage prostate cancer.

Partnerships and Intellectual Property

• Recently secured exclusive in-licenses for dendritic cell technology, further solidifying their leading position in the dendritic cell franchise.

Note: The information provided is based solely on the available data. Aspects like founding details, employee count, and revenue metrics were not furnished and thus are not included in this report.